Symbols

BPMC(Delisted)

Blueprint Medicines·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 1

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About BPMC

Blueprint Medicines Corporation

A global precision therapy company that invents life-changing therapies for people with cancer and blood disorders

Industry

Established Date

10/14/2008

Listing Date

04/30/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

649

Fiscal Year Ends

12-31

Website

www.blueprintmedicines.com

Security Type

Common stock

Office address

45 Sidney Street , Cambridge, MA, 02139

Business

Introduction

Founded in Delaware on October 14, 2008, Blueprint Medicines Corporation is a biopharmaceutical company focused on improving patients' lives defined by diseases driven by abnormally activated protein kinase genomes. The company's approach is to systematically and reproducibly identify kinases that are genomic disease definition drivers and craft drug candidates with therapeutic windows that provide remarkable and durable clinical responses to patients. The company is committed to almost all efforts in R & D, initial market development, and capital improvement. The company is dependent on other early-stage companies with similar risks, including key individuals; needs to develop commercially viable drugs; other companies, many of which are bigger and better capitalized; and needs to obtain sufficient additional funding to fund the development of its drugs. If the company is unable to raise capital when needed or on attractive terms, this will be forced to delay, reduce, eliminate or exceed certain research and development programs or future commercialization efforts that license it.

Earnings Call

Q1/2025

Estimate EPS-0.44

Actual EPS0.01

Estimate Revenue156.89M

Actual Revenue149.41M

Blueprint Medicines' Q1 2025: Navigating Contradictions in Market Growth, Free Goods, and Clinical Strategy

May 07,2025 07:24·
Earnings Decrypt

Company Financials

EPS

BPMC has released its 2025 Q1 earnings. EPS was reported at 0.01, versus the expected -0.44, beating expectations. The chart below visualizes how BPMC has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

BPMC has released its 2025 Q1 earnings report, with revenue of 149.41M, reflecting a YoY change of 55.45%, and net profit of 496.00K, showing a YoY change of -99.44%. The Sankey diagram below clearly presents BPMC's revenue sources and cost distribution.